BE2015C053I2 - - Google Patents

Download PDF

Info

Publication number: BE2015C053I2
Authority: BE; Belgium

Application number

BE2015C053C

Other languages

French (fr)

Original Assignee

Janssen Sciences Ireland Unlimited Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-09-03

Filing date

2015-10-21

Publication date

2023-12-14

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34280181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2015C053(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-10-21 Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co

2023-12-14 Publication of BE2015C053I2 publication Critical patent/BE2015C053I2/fr

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Engineering & Computer Science (AREA)
Oncology (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Communicable Diseases (AREA)
AIDS & HIV (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)

BE2015C053C 2003-09-03 2015-10-21 BE2015C053I2 (de)

Applications Claiming Priority (8)

Application Number	Priority Date	Filing Date	Title
US49977103P	2003-09-03	2003-09-03
EP03103275		2003-09-03
EP03103319		2003-09-08
EP03103335		2003-09-10
EP03103668		2003-10-02
US50848603P	2003-10-03	2003-10-03
EP04787096.9A EP1663240B2 (de)	2003-09-03	2004-09-03	Kombinationen eines pyrimidins mit nnrti und rt-hemmern
PCT/EP2004/052028 WO2005021001A1 (en)	2003-09-03	2004-09-03	Combinations of a pyrimidine containing nnrti with rt inhibitors

Publications (1)

Publication Number	Publication Date
BE2015C053I2 true BE2015C053I2 (de)	2023-12-14

Family

ID=34280181

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BE2015C053C BE2015C053I2 (de)	2003-09-03	2015-10-21

Country Status (24)

Country	Link
US (9)	US20080200435A1 (de)
EP (1)	EP1663240B2 (de)
JP (3)	JP5507791B2 (de)
KR (1)	KR20060090658A (de)
CN (1)	CN101060844B (de)
AP (1)	AP2109A (de)
AU (5)	AU2004268390B2 (de)
BE (1)	BE2015C053I2 (de)
CA (1)	CA2537095C (de)
CY (5)	CY2015039I1 (de)
FI (1)	FI1663240T4 (de)
FR (5)	FR15C0071I2 (de)
HR (1)	HRP20150798T4 (de)
HU (5)	HUS1500053I1 (de)
IL (2)	IL173438A (de)
LT (2)	LTPA2016045I1 (de)
LU (3)	LU92853I2 (de)
MX (1)	MXPA06002437A (de)
MY (1)	MY169670A (de)
NL (2)	NL300781I2 (de)
NO (6)	NO334877B1 (de)
NZ (1)	NZ545306A (de)
PL (1)	PL1663240T5 (de)
WO (1)	WO2005021001A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY169670A (en)	2003-09-03	2019-05-08	Tibotec Pharm Ltd	Combinations of a pyrimidine containing nnrti with rt inhibitors
US8101629B2 (en)	2001-08-13	2012-01-24	Janssen Pharmaceutica N.V.	Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US7638522B2 (en)	2001-08-13	2009-12-29	Janssen Pharmaceutica N.V.	Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
JO3429B1 (ar)	2001-08-13	2019-10-20	Janssen Pharmaceutica Nv	مشتقات برميدينات مثبطة فيروس الايدز
KR101140785B1 (ko)	2002-08-09	2012-05-03	얀센 파마슈티카 엔.브이.	4-〔〔4-〔〔4-（2-시아노에테닐）-2,6-디메틸페닐〕아미노〕-2-피리미디닐〕아미노〕벤조니트릴의 제조방법
MXPA05007016A (es)	2003-01-14	2005-09-12	Gilead Sciences Inc	Composiciones y metodos para terapia antiviral de combinacion.
ATE550074T1 (de) *	2004-09-02	2012-04-15	Janssen Pharmaceutica Nv	Fumarat aus 4-((4-((4-(2-cyanoethenyl)-2,6- dimethylphenyl amino -2-pyrimidinyl amino benzonitril
WO2006024667A1 (en) *	2004-09-02	2006-03-09	Janssen Pharmaceutica N.V.	Furamate of 4-( (4-( (4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile
CA2577288C (en) *	2004-09-02	2010-11-30	Janssen Pharmaceutica N.V.	Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
UA92469C2 (en) *	2004-09-02	2010-11-10	Янссен Фармацевтика Н.В.	Fumarate of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl amino benzonitrile
ATE508748T1 (de) *	2004-09-02	2011-05-15	Janssen Pharmaceutica Nv	Salz von 4-ää4-ää4-(2-cyanoethenyl)-2,6- dimethylphenylüaminoü-2- pyrimidinylüaminoübenzonitril.
TW201414495A (zh) *	2005-04-04	2014-04-16	Tibotec Pharm Ltd	Ｈｉｖ-感染之預防
TWI471145B (zh) *	2005-06-13	2015-02-01	Bristol Myers Squibb & Gilead Sciences Llc	單一式藥學劑量型
TWI375560B (en)	2005-06-13	2012-11-01	Gilead Sciences Inc	Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
ATE474560T1 (de) *	2005-12-14	2010-08-15	Cipla Ltd	Pharmazeutische kombination aus nucleotid und nucleosid-reverse-transkriptase-hemmern (wie tenofovir und lamivudin) in verschiedenen teilen der dosiereinheit
BRPI0707179A2 (pt) *	2006-01-20	2011-04-26	Tibotec Pharm Ltd	tratamento de longo termo de infecção por hiv
US9044509B2 (en)	2006-02-03	2015-06-02	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Inhibition of HIV infection through chemoprophylaxis
FR2903312B1 (fr)	2006-07-05	2008-09-26	Univ Aix Marseille Ii	Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament
CL2008000746A1 (es) *	2007-03-14	2008-09-22	Tibotec Pharm Ltd	Composicion farmaceutica en solucion que comprende tmc278 y un polimero soluble en agua; proceso de preparacion de dicha composicion; y uso de un polvo que comprende tmc278 para tratar sida.
SG10201408158SA (en)	2008-01-03	2015-03-30	Univ Aix Marseille	Composition and methods used during anti-hiv treatment
WO2010072844A1 (en) *	2008-12-24	2010-07-01	Tibotec Pharmaceuticals	Implantable devices for treating hiv
UA112155C2 (uk)	2009-12-21	2016-08-10	ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі	Розкладаний видалюваний імплантат для безперервного вивільнення активної сполуки
PE20121524A1 (es)	2010-01-27	2012-12-03	Viiv Healthcare Co	Combinaciones de compuestos que comprenden inhibidores de la integrasa de vih y otros agentes terapeuticos
SG10201509521WA (en)	2010-11-19	2015-12-30	Gilead Sciences Inc	Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
WO2012125993A1 (en)	2011-03-17	2012-09-20	Teva Pharmaceutical Industries Ltd.	Solid state forms of rilpivirine base, and rilipivirine salts
WO2013038425A1 (en) *	2011-09-16	2013-03-21	Hetero Research Foundation	Rilpivirine hydrochloride
EA030003B1 (ru)	2012-12-21	2018-06-29	Джилид Сайэнс, Инк.	Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции
SG11201802983TA (en)	2015-11-09	2018-05-30	Gilead Sciences Inc	Therapeutic compositions for treatment of human immunodeficiency virus
WO2018077815A1 (en)	2016-10-24	2018-05-03	Janssen Sciences Ireland Uc	Dispersible compositions
WO2018119371A1 (en) *	2016-12-23	2018-06-28	Temple University - Of The Commonwealth System Of Higher Education	Anti-flaviviridae activity of anti-retroviral non-nucleoside (nnrtis) and nucleoside reverse transcriptase inhibitors (nnrtis)
RU2019136678A (ru) *	2017-04-18	2021-05-18	Сипла Лимитед	Комбинированная терапия для применения в лечении ретровирусных инфекций
WO2019021319A1 (en) *	2017-07-27	2019-01-31	Cipla Limited	PHARMACEUTICAL COMPOSITIONS
CN115397422A (zh)	2019-11-29	2022-11-25	西皮欧生命科学有限公司	包含利匹韦林的组合物和其用于治疗肿瘤或癌症的用途

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5182111A (en) *	1987-11-17	1993-01-26	Boston University Research Foundation	In vivo delivery of active factors by co-cultured cell implants
US5047407A (en)	1989-02-08	1991-09-10	Iaf Biochem International, Inc.	2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB8815265D0 (en)	1988-06-27	1988-08-03	Wellcome Found	Therapeutic nucleosides
US5368864A (en) *	1988-11-25	1994-11-29	Henning Berlin Gmbh Chemie- Und Pharmawerk	Formulation of oxypurinol and/or its alkali and alkaline earth salts
MY104575A (en)	1989-12-22	1994-04-30	The Wellcome Foundation Ltd	Therapeutic nucleosides.
EP0489181B1 (de)	1990-07-19	1996-10-02	Otsuka Pharmaceutical Co., Ltd.	Feste zusammensetzung
US5145684A (en)	1991-01-25	1992-09-08	Sterling Drug Inc.	Surface modified drug nanoparticles
EP0610441A4 (de) *	1991-10-29	1996-01-10	Clover Cons Ltd	Vernetzbare polysacchariden, polykationen und lipiden verwendbar zum einkapseln und abgabe von arzneimitteln.
ATE184787T1 (de)	1992-05-13	1999-10-15	Wellcome Found	Therapeutische kombinationen
JPH06316524A (ja)	1992-09-11	1994-11-15	Naoyuki Inoue	抗エイズウイルス剤
TW401303B (en) *	1994-07-01	2000-08-11	Janssen Pharmaceutica Nv	Anti-HIV triple combination
IT1281502B1 (it) *	1995-06-13	1998-02-18	Sardinian Antiviral Research C	Impiego di un inibitore non nucleosidico della trascrittasi inversa in associazione con inibitori nucleosidici per il trattamento della
US6045829A (en) *	1997-02-13	2000-04-04	Elan Pharma International Limited	Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
ATE296091T1 (de)	1999-09-21	2005-06-15	Skyepharma Canada Inc	Oberflächenmodifizierte teilchenförmige zusammensetzungen biologisch aktiver stoffe
US6743446B2 (en) *	1999-12-15	2004-06-01	The Ohio State University Research Foundation	Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers
TWI284048B (en) *	2000-01-27	2007-07-21	Zentaris Ag	Compressed microparticles for dry injection
CN1187052C (zh)	2000-03-30	2005-02-02	布里斯托尔-迈尔斯斯奎布公司	含有司他夫定(stavudine)的持续释放微球
US20040115268A1 (en) *	2000-04-26	2004-06-17	Control Delivery Systems, Inc.	Systemic delivery of antiviral agents
DE10050199A1 (de)	2000-10-11	2002-04-25	Ethicon Gmbh	Flächiges Implantat mit im Ultraschall detektierbaren Elementen
CA2431319A1 (en)	2000-12-11	2002-06-20	Hiroto Bando	Pharmaceutical composition having an improved water solubility
WO2003000235A1 (en)	2001-06-22	2003-01-03	Pfizer Products Inc.	Pharmaceutical compositions of dispersions of drugs and neutral polymers
MY169670A (en)	2003-09-03	2019-05-08	Tibotec Pharm Ltd	Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar) *	2001-08-13	2019-10-20	Janssen Pharmaceutica Nv	مشتقات برميدينات مثبطة فيروس الايدز
EP1458361A4 (de)	2001-11-20	2007-04-25	Advanced Inhalation Res Inc	Zusammensetzungen zur abgabe von produkten mit anhaltender wirkung
KR101140785B1 (ko)	2002-08-09	2012-05-03	얀센 파마슈티카 엔.브이.	4-〔〔4-〔〔4-（2-시아노에테닐）-2,6-디메틸페닐〕아미노〕-2-피리미디닐〕아미노〕벤조니트릴의 제조방법
WO2004022033A1 (en) *	2002-09-04	2004-03-18	Microchips, Inc.	Method and device for the controlled delivery of parathyroid hormone
US20050287177A1 (en)	2002-11-08	2005-12-29	Glaxo Group Unlimited And Smithkline Beecham Corp.	Pharmaceutical compositions
JP2006508145A (ja)	2002-11-15	2006-03-09	テイボテク・フアーマシユーチカルズ・リミテツド	抗感染化合物としての置換インドールピリジニウム
AU2002350719A1 (en)	2002-11-29	2004-06-23	Janssen Pharmaceutica N.V.	Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
BRPI0407329A (pt)	2003-02-07	2006-01-10	Janssen Pharmaceutica Nv	Derivados de pirimidina para a prevenção de infecção de hiv
KR100629771B1 (ko) *	2004-01-27	2006-09-28	씨제이 주식회사	결정성이 감소되거나 무정형화된 올티프라즈의 제조방법
KR20120039763A (ko)	2004-06-08	2012-04-25	버텍스 파마슈티칼스 인코포레이티드	약학 조성물
MY191349A (en)	2004-08-27	2022-06-17	Bayer Pharmaceuticals Corp	New pharmaceutical compositions for the treatment of hyper-proliferative disorders
CA2577288C (en)	2004-09-02	2010-11-30	Janssen Pharmaceutica N.V.	Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
ATE508748T1 (de)	2004-09-02	2011-05-15	Janssen Pharmaceutica Nv	Salz von 4-ää4-ää4-(2-cyanoethenyl)-2,6- dimethylphenylüaminoü-2- pyrimidinylüaminoübenzonitril.
AU2005307797B2 (en)	2004-11-16	2011-06-02	Alkermes Pharma Ireland Limited	Injectable nanoparticulate olanzapine formulations
TW201414495A (zh)	2005-04-04	2014-04-16	Tibotec Pharm Ltd	Ｈｉｖ-感染之預防
EP1872390A2 (de) *	2005-04-11	2008-01-02	The Board of Trustees of the Leland Stanford Junior University	Mehrschichtige struktur mit vorgegebenem schichtmuster mit einem wirkstoff
TW200710091A (en)	2005-04-11	2007-03-16	Tibotec Pharm Ltd	(1,10B-dihydro-2-(aminoalkyl-phenyl)-5H-pyrazolo [1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors
WO2006131806A2 (en)	2005-06-07	2006-12-14	Pfizer Products Inc.	Multiparticulates comprising low-solubility drugs and carriers that result in rapid drug release
CN101272769B (zh)	2005-07-28	2013-04-24	Isp投资有限公司	生物利用度提高的苯醌类化合物
BRPI0707179A2 (pt)	2006-01-20	2011-04-26	Tibotec Pharm Ltd	tratamento de longo termo de infecção por hiv
EP2040671B1 (de)	2006-06-23	2018-01-24	Janssen Sciences Ireland UC	Wässrige suspensionen von tmc278
WO2008060360A2 (en) *	2006-09-28	2008-05-22	Surmodics, Inc.	Implantable medical device with apertures for delivery of bioactive agents
CL2008000746A1 (es)	2007-03-14	2008-09-22	Tibotec Pharm Ltd	Composicion farmaceutica en solucion que comprende tmc278 y un polimero soluble en agua; proceso de preparacion de dicha composicion; y uso de un polvo que comprende tmc278 para tratar sida.
SI2175857T1 (sl)	2007-07-12	2014-01-31	Janssen R&D Ireland	Kristalna oblika (E) 4-((4-((4-(2-cianoetenil)-2,6-dimetilfenil)amino) 2-pirimidinil)amino)benzonitrila
WO2009046299A2 (en)	2007-10-04	2009-04-09	Boston Scientific Scimed, Inc	Implantable drug depot for intrathecal drug delivery system for pain management
US20110257111A1 (en) *	2008-10-24	2011-10-20	Harbeson Scott L	Hydroxyethlamino Sulfonamide Derivatives

2004
- 2004-09-02 MY MYPI20043578A patent/MY169670A/en unknown
- 2004-09-03 AU AU2004268390A patent/AU2004268390B2/en not_active Expired
- 2004-09-03 WO PCT/EP2004/052028 patent/WO2005021001A1/en not_active Ceased
- 2004-09-03 MX MXPA06002437A patent/MXPA06002437A/es active IP Right Grant
- 2004-09-03 AP AP2006003551A patent/AP2109A/en active
- 2004-09-03 PL PL04787096.9T patent/PL1663240T5/pl unknown
- 2004-09-03 JP JP2006525150A patent/JP5507791B2/ja not_active Expired - Lifetime
- 2004-09-03 KR KR1020067003074A patent/KR20060090658A/ko not_active Ceased
- 2004-09-03 NZ NZ545306A patent/NZ545306A/en not_active IP Right Cessation
- 2004-09-03 EP EP04787096.9A patent/EP1663240B2/de not_active Expired - Lifetime
- 2004-09-03 CN CN2004800254267A patent/CN101060844B/zh not_active Expired - Lifetime
- 2004-09-03 US US10/570,228 patent/US20080200435A1/en not_active Abandoned
- 2004-09-03 CA CA2537095A patent/CA2537095C/en not_active Expired - Lifetime
2006
- 2006-01-30 IL IL173438A patent/IL173438A/en active Protection Beyond IP Right Term
- 2006-03-27 NO NO20061374A patent/NO334877B1/no active Protection Beyond IP Right Term
2009
- 2009-10-07 US US12/574,881 patent/US8841310B2/en not_active Expired - Lifetime
2011
- 2011-03-14 AU AU2011201123A patent/AU2011201123B2/en not_active Expired
- 2011-05-24 IL IL213104A patent/IL213104A/en active IP Right Grant
- 2011-10-12 JP JP2011224982A patent/JP2012051915A/ja not_active Withdrawn
2014
- 2014-06-26 AU AU2014203484A patent/AU2014203484B2/en active Active
- 2014-08-07 US US14/454,045 patent/US20140349971A1/en not_active Abandoned
- 2014-10-31 JP JP2014222770A patent/JP5820045B2/ja not_active Expired - Lifetime
- 2014-12-18 NO NO2014031C patent/NO2014031I1/no not_active IP Right Cessation
- 2014-12-18 NO NO2014032C patent/NO2014032I1/no unknown
- 2014-12-18 NO NO2014030C patent/NO2014030I1/no unknown
2015
- 2015-06-19 US US14/744,501 patent/US20150283135A1/en not_active Abandoned
- 2015-07-20 HR HRP20150798TT patent/HRP20150798T4/hr unknown
- 2015-10-20 NL NL300781C patent/NL300781I2/nl unknown
- 2015-10-20 LU LU92853C patent/LU92853I2/xx unknown
- 2015-10-21 FR FR15C0071C patent/FR15C0071I2/fr active Active
- 2015-10-21 FR FR15C0072C patent/FR15C0072I2/fr active Active
- 2015-10-21 FR FR15C0073C patent/FR15C0073I2/fr active Active
- 2015-10-21 CY CY2015039C patent/CY2015039I1/el unknown
- 2015-10-21 BE BE2015C053C patent/BE2015C053I2/fr unknown
- 2015-10-21 LU LU92855C patent/LU92855I2/xx unknown
- 2015-10-21 HU HUS1500053C patent/HUS1500053I1/hu unknown
- 2015-10-21 CY CY2015038C patent/CY2015038I2/el unknown
- 2015-10-21 NL NL300768C patent/NL300768I2/nl unknown
- 2015-10-21 CY CY2015040C patent/CY2015040I1/el unknown
- 2015-10-21 HU HUS1500052C patent/HUS1500052I1/hu unknown
- 2015-10-21 LU LU92854C patent/LU92854I2/xx unknown
- 2015-10-21 HU HUS1500054C patent/HUS1500054I1/hu unknown
2016
- 2016-08-05 AU AU2016210733A patent/AU2016210733B2/en active Active
- 2016-12-19 US US15/383,076 patent/US20170100398A1/en not_active Abandoned
- 2016-12-20 NO NO2016025C patent/NO2016025I1/no unknown
- 2016-12-20 FR FR16C1022C patent/FR16C1022I1/fr active Active
- 2016-12-20 NO NO2016026C patent/NO2016026I1/no unknown
- 2016-12-20 CY CY2016048C patent/CY2016048I1/el unknown
- 2016-12-20 FR FR16C1024C patent/FR16C1024I1/fr active Active
- 2016-12-20 CY CY2016049C patent/CY2016049I1/el unknown
- 2016-12-20 FI FIEP04787096.9T patent/FI1663240T4/fi active
- 2016-12-20 LT LTPA2016045C patent/LTPA2016045I1/lt unknown
- 2016-12-20 HU HUS1600059C patent/HUS1600059I1/hu unknown
- 2016-12-20 HU HUS1600058C patent/HUS1600058I1/hu unknown
- 2016-12-20 LT LTPA2015035C patent/LTC1663240I2/lt unknown
2018
- 2018-04-11 US US15/950,548 patent/US20180228800A1/en not_active Abandoned
2019
- 2019-02-06 AU AU2019200813A patent/AU2019200813A1/en not_active Abandoned
- 2019-03-21 US US16/360,693 patent/US20190216807A1/en not_active Abandoned
2020
- 2020-02-07 US US16/784,404 patent/US20200171027A1/en not_active Abandoned
2021
- 2021-09-13 US US17/472,870 patent/US20220008417A1/en not_active Abandoned

Also Published As

Publication number	Publication date
LTPA2016044I1 (lt)	2017-01-10
NO2016025I1 (de)	2016-12-20
CY2015038I1 (el)	2016-08-31
NO2014032I1 (no)	2015-01-05
AU2014203484A1 (en)	2014-07-17
HRP20150798T4 (hr)	2023-06-09
HRP20150798T1 (hr)	2015-09-11
IL173438A (en)	2012-03-29
FR15C0072I2 (fr)	2019-05-17
NZ545306A (en)	2009-11-27
US20220008417A1 (en)	2022-01-13
IL213104A (en)	2016-02-29
NO2014032I2 (no)	2014-12-18
EP1663240B1 (de)	2015-04-22
NO2014031I2 (no)	2014-12-18
PL1663240T3 (pl)	2015-10-30
HUS1500054I1 (hu)	2016-03-29
NO2016026I1 (no)	2016-12-20
US20180228800A1 (en)	2018-08-16
FR15C0073I2 (fr)	2016-02-12
US20170100398A1 (en)	2017-04-13
EP1663240A1 (de)	2006-06-07
LU92855I2 (fr)	2015-12-21
FR16C1024I1 (fr)	2017-02-03
US20150283135A1 (en)	2015-10-08
NL300768I1 (de)	2015-12-16
NO2014030I1 (no)	2015-01-05
CN101060844A (zh)	2007-10-24
CY2015040I2 (el)	2016-08-31
WO2005021001A1 (en)	2005-03-10
JP5507791B2 (ja)	2014-05-28
AU2016210733A1 (en)	2016-08-25
US8841310B2 (en)	2014-09-23
LU92854I2 (fr)	2015-12-21
NO20061374L (no)	2006-03-27
AU2004268390A1 (en)	2005-03-10
FR15C0072I1 (de)	2015-04-12
AU2016210733B2 (en)	2018-11-08
AU2019200813A1 (en)	2019-02-28
CY2015038I2 (el)	2016-08-31
CA2537095C (en)	2012-05-29
CY2016049I2 (el)	2017-07-12
JP2007520443A (ja)	2007-07-26
JP2012051915A (ja)	2012-03-15
LTC1663240I2 (lt)	2022-05-25
HUS1500053I1 (hu)	2016-03-29
NL300781I1 (de)	2016-04-19
MY169670A (en)	2019-05-08
NL300768I2 (nl)	2023-08-09
US20200171027A1 (en)	2020-06-04
MXPA06002437A (es)	2006-06-20
KR20060090658A (ko)	2006-08-14
US20080200435A1 (en)	2008-08-21
FR15C0071I1 (de)	2015-04-12
NO2014031I1 (no)	2015-01-05
AU2004268390B2 (en)	2011-03-31
CY2015040I1 (el)	2016-08-31
CY2016049I1 (el)	2017-07-12
US20190216807A1 (en)	2019-07-18
IL173438A0 (en)	2006-06-11
AP2006003551A0 (en)	2006-04-30
CY2015039I2 (el)	2016-08-31
HUS1600058I1 (hu)	2017-02-28
JP2015044839A (ja)	2015-03-12
EP1663240B2 (de)	2023-03-01
NO2014030I2 (no)	2014-12-18
CY2015039I1 (el)	2016-08-31
CA2537095A1 (en)	2005-03-10
CN101060844B (zh)	2012-01-04
HUS1500052I1 (hu)	2016-03-29
HK1092698A1 (en)	2007-02-16
NL300781I2 (de)	2016-04-19
CY2016048I2 (el)	2017-07-12
HUS1600059I1 (hu)	2017-02-28
NO334877B1 (no)	2014-06-23
PL1663240T5 (pl)	2024-02-26
AU2011201123A1 (en)	2011-04-07
CY2016048I1 (el)	2017-07-12
JP5820045B2 (ja)	2015-11-24
AU2011201123B2 (en)	2013-10-10
FR16C1022I1 (fr)	2017-02-03
US20100029591A1 (en)	2010-02-04
US20140349971A1 (en)	2014-11-27
AU2014203484B2 (en)	2016-09-29
LTPA2016045I1 (lt)	2017-01-10
LU92853I2 (fr)	2015-12-21
FI1663240T4 (fi)	2023-04-25
FR15C0071I2 (fr)	2016-02-12
IL213104A0 (en)	2011-07-31
AP2109A (en)	2010-02-26
FR15C0073I1 (de)	2015-04-12

Publication	Publication Date	Title
NO2016025I1 (de)	2016-12-20
BE2013C067I2 (de)	2023-08-09
BE2013C038I2 (de)	2023-12-14
BE2013C036I2 (de)	2023-12-14
BE2011C030I2 (de)	2023-03-07
JP2004032725A5 (de)	2006-06-22
JP2004003080A5 (de)	2005-09-02
JP2004001496A5 (de)	2006-06-08
JP2004005486A5 (de)	2006-04-06
BE2013C034I2 (de)	2024-08-08
JP2004032700A5 (de)	2006-06-08
BE2012C053I2 (de)	2023-08-09
JP2004160186A5 (de)	2008-03-13
JP2004002666A5 (de)	2005-10-27
JP2004164542A5 (de)	2005-07-07
JP2004088759A5 (de)	2005-11-04
JP2004035109A5 (de)	2006-03-23
JP2003337765A5 (de)	2006-05-18
JP2004006886A5 (de)	2005-09-22
JP2004216407A5 (de)	2006-02-02
JP2003250284A5 (de)	2006-10-19
FR2828815A3 (de)	2003-02-28
AU2003207750A1 (de)	2003-09-18
AU2002324323A1 (de)	2003-06-05
AU2002316511A1 (de)	2003-05-15